RAYAIR 5 MG TABLET

RAYAIR 5 MG TABLET contains Montelukast Sodium as its active ingredient. It is a leukotriene receptor antagonist used for the treatment and management of asthma, allergic rhinitis, and exercise-induced bronchoconstriction. Montelukast works by blocking the action of leukotrienes, which are inflammatory mediators involved in various allergic and asthmatic conditions.

Mechanism of Action:

Montelukast Sodium exerts its pharmacological effects by selectively antagonizing leukotriene receptors, specifically cysteinyl leukotriene receptors CysLT1. By inhibiting the binding of leukotrienes to their receptors, Montelukast prevents the bronchoconstrictive and inflammatory effects mediated by leukotrienes, thus alleviating symptoms associated with asthma and allergic rhinitis.

Uses:

RAYAIR 5 MG TABLET is indicated for the following conditions:

• Asthma: For the prophylaxis and chronic treatment of asthma in adults and pediatric patients aged 12 months and older.
• Allergic Rhinitis: For the relief of symptoms associated with allergic rhinitis, including nasal congestion, sneezing, itching, and rhinorrhea, in adults and pediatric patients aged 2 years and older.
• Exercise-Induced Bronchoconstriction: For the prevention of exercise-induced bronchoconstriction in patients aged 6 years and older.

Dosage and Administration:

The recommended dosage of RAYAIR 5 MG TABLET may vary depending on the patient’s age, condition, and response to treatment. It is usually taken orally, once daily in the evening, with or without food. It is important to follow the dosage instructions provided by the healthcare provider.

Side Effects:

Common side effects associated with RAYAIR tablet may include:

• Headache
• Abdominal pain
• Nausea
• Diarrhea
• Fatigue
• Upper respiratory tract infection
• Cough
• Dizziness

Precautions:

• RAYAIR 5 MG TABLET should be used with caution in patients with a history of hepatic impairment or phenylketonuria (as the tablet formulation contains phenylalanine).
• It should not be used for the treatment of acute asthma attacks or status asthmaticus. Patients should have appropriate rescue medication available for such situations.
• Montelukast should be discontinued if neuropsychiatric symptoms such as agitation, aggression, anxiety, hallucinations, depression, insomnia, or suicidal thinking and behavior occur.
• Patients should be advised to seek medical attention if they experience any worsening of asthma symptoms or significant changes in behavior or mood.

Conclusion:

RAYAIR 5 MG TABLET, containing Montelukast Sodium, is a valuable medication for the management of asthma and allergic rhinitis. By targeting leukotriene receptors, it helps alleviate symptoms associated with these conditions and improves overall quality of life for patients.